Silexion Therapeutics faces a precarious financial outlook as it attempts to advance its LODER platform without a commercial revenue stream to offset significant R&D expenditures.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$5.17+75.6% vs -$21.20 | — vs — |
Q2 2026 May 15, 2026 | -$0.85+34.1% vs -$1.29 | — vs — |
Q2 2026 May 12, 2026 | -$8.50+34.1% vs -$12.90 | — vs — |
Q2 2026 Mar 17, 2026 | -$23.85-1938.5% vs -$1.17 | — vs — |
Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic cancer
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company's ordinary shares originally issued in August 2026 having a reduced exercise price of $0.2603 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-298137). The gross proceeds to the Company from the exercise of the warrants are expected to be $837,366.36, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.
Translational research demonstrates that SIL204 utilizes native serum lipids to facilitate intracellular delivery and robust KRAS oncogene knockdown
Grand Cayman, Cayman Islands, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that members of its management team will participate in the following industry and investor conferences in September 2026: Oncology & Immunology Innovation Partnering & Licensing Summit Presentation date: September 9, 2026 Location: Hotel Commonwealth, Boston, MA Format: Presentation Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer 8th Annual RAS-Targeted Drug Development Summit Presentation date: September 10, 2026 Location: The Colonnade Hotel, Boston, MA Format: Presentation Presenter: Dr. Mitchell Shirvan, Chief Scientific and Development Officer H.C.
Benchmark SLXN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Silexion Therapeutics Ltd. (SLXN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.15 | $99.8K | -0.01 | — | — | -563.11% | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $58.16 | $8.19B | -26.06 | 23258.15% | -47.79% | -60.05% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $904.35 | $93.17B | 19.82 | 0.99% | 28.51% | 15.07% | 0.38% |
Silexion Therapeutics Ltd. (SLXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Silexion Therapeutics Ltd. (SLXN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 21, 2026·SEC
Aug 14, 2026·SEC
Aug 13, 2026·SEC
Mar 17, 2026·SEC
Get notified when SLXN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Silexion Therapeutics Ltd. (SLXN) stock FAQ — growth, dividends, profitability & financials explained
No. Silexion Therapeutics Ltd. (SLXN) reported a net loss of $14.0M over the trailing twelve months.
Silexion Therapeutics Ltd. (SLXN) had a return on equity (ROE) of -563.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Silexion Therapeutics Ltd. (SLXN) had negative free cash flow of $12.4M over the trailing twelve months.
